314 related articles for article (PubMed ID: 25814348)
1. Hybrid ABSORB bioresorbable vascular scaffold and drug eluting stent or hybrid BVS-DES percutaneous coronary intervention: Method and rationale for hybrid overlapping PCI.
Yew KL
Int J Cardiol; 2015; 186():74-6. PubMed ID: 25814348
[No Abstract] [Full Text] [Related]
2. Further elucidation on "Hybrid ABSORB bioresorbable vascular scaffold and drug eluting stent or hybrid BVS-DES percutaneous coronary intervention: Method and rationale for hybrid overlapping PCI".
Yew KL
Int J Cardiol; 2015 Jul; 191():170-1. PubMed ID: 25965626
[No Abstract] [Full Text] [Related]
3. Letter regarding "Hybrid ABSORB bioresorbable vascular scaffold and drug eluting stent or hybrid BVS-DES percutaneous coronary intervention: Method and rationale for hybrid overlapping PCI".
Granata F; Moscarella E; Varricchio A
Int J Cardiol; 2015 Jul; 190():7-8. PubMed ID: 25912107
[No Abstract] [Full Text] [Related]
4. Clinical Comparison With Short-Term Follow-Up of Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Stent in Primary Percutaneous Coronary Interventions.
Cortese B; Ielasi A; Romagnoli E; Varricchio A; Cuculo A; Loi B; Pisano F; Corrado D; Sesana M; La Vecchia L; Summaria F; Tespili M; Silva Orrego P; Tognoni G; Steffenino G
Am J Cardiol; 2015 Sep; 116(5):705-10. PubMed ID: 26100584
[TBL] [Abstract][Full Text] [Related]
5. Overlapping technique for hybrid percutaneous coronary intervention strategy utilising drug eluting stent and ABSORB bioresorbable vascular scaffold.
Yew KL
Int J Cardiol; 2015 Jan; 178():e8-e10. PubMed ID: 25205484
[No Abstract] [Full Text] [Related]
6. Subacute recoil in bioresorbable vascular scaffold in a complex coronary lesion: A lesson from daily clinical practice.
Centola M; Lucreziotti S; Salerno-Uriarte D; Tresoldi S; Cannone G; Sponzilli C; Carugo S
Int J Cardiol; 2016 Jan; 203():995-6. PubMed ID: 26625328
[No Abstract] [Full Text] [Related]
7. A hybrid strategy with bioresorbable vascular scaffolds and drug eluting stents for treating complex coronary lesions.
Jabbour RJ; Ielasi A; Tanaka A; Leoncini M; Cortese B; Grigis G; Mitomo S; Regazzoli D; Di Palma G; Rapetto C; Tespili M; Colombo A; Latib A
Cardiovasc Revasc Med; 2017; 18(5S1):S4-S9. PubMed ID: 28314675
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of bioresorbable vascular scaffold in ST-elevation myocardial infarction.
de Hemptinne Q; Picard F; Ly HQ; Ibrahim R; Asgar AW; de Guise P; Doucet S; Dorval JF; Marquis-Gravel G; Levi M; L-L'allier P; Tanguay JF
Acta Cardiol; 2018 Jun; 73(3):276-281. PubMed ID: 28954592
[TBL] [Abstract][Full Text] [Related]
9. The use of bioresorbable vascular scaffold Absorb BVS® in patients with stable coronary artery disease: one-year results with special focus on the hybrid bioresorbable vascular scaffolds and drug eluting stents treatment.
Gil RJ; Bil J; Pawłowski T; Yuldashev N; Kołakowski L; Jańczak J; Jabłoński W; Paliński P
Kardiol Pol; 2016; 74(7):627-33. PubMed ID: 26779846
[TBL] [Abstract][Full Text] [Related]
10. Intraindividual Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Drug-Eluting Metallic Stents.
Cassese S; Hoppmann P; Kufner S; Byrne RA; Wiebe J; Colleran R; Giacoppo D; Harada Y; Laugwitz KL; Schunkert H; Fusaro M; Kastrati A
Circ Cardiovasc Interv; 2016 Aug; 9(8):. PubMed ID: 27512088
[TBL] [Abstract][Full Text] [Related]
11. The Current Literature on Bioabsorbable Stents: a Review.
Omar WA; Kumbhani DJ
Curr Atheroscler Rep; 2019 Nov; 21(12):54. PubMed ID: 31768641
[TBL] [Abstract][Full Text] [Related]
12. Everolimus-eluting bioresorbable vascular scaffolds versus second generation drug-eluting stents for percutaneous treatment of chronic total coronary occlusions: Technical and procedural outcomes from the GHOST-CTO registry.
La Manna A; Chisari A; Giacchi G; Capodanno D; Longo G; Di Silvestro M; Capranzano P; Tamburino C
Catheter Cardiovasc Interv; 2016 Nov; 88(6):E155-E163. PubMed ID: 26756959
[TBL] [Abstract][Full Text] [Related]
13. The absorb bioresorbable vascular scaffold in coronary bifurcations: insights from bench testing.
Džavík V; Colombo A
JACC Cardiovasc Interv; 2014 Jan; 7(1):81-8. PubMed ID: 24332424
[TBL] [Abstract][Full Text] [Related]
14. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials.
Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW;
JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836
[TBL] [Abstract][Full Text] [Related]
15. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B
Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Safety of Everolimus-Eluting Bioresorbable Vascular Scaffold (BVS) Implantation in Patients With Chronic Total Coronary Occlusions: Acute Procedural and Short-Term Clinical Results.
Goktekin O; Yamac AH; Latib A; Tastan A; Panoulas VF; Sato K; Erdogan E; Uyarel H; Shah I; Colombo A
J Invasive Cardiol; 2015 Oct; 27(10):461-6. PubMed ID: 26429848
[TBL] [Abstract][Full Text] [Related]
17. Bioresorbable vascular scaffold for coronary in-stent restenosis: a novel concept.
Deora S; Shah S; Pancholy S; Patel T
Indian Heart J; 2014; 66(4):459-61. PubMed ID: 25173206
[TBL] [Abstract][Full Text] [Related]
18. [Hybrid percutaneous coronary intervention with drug-eluting stent in combination with bioresorbable vascular scaffolds for complex coronary lesions].
Fineschi M; Carrera A; Pierli C
G Ital Cardiol (Rome); 2017 Sep; 18(9 Suppl 1):21S-23S. PubMed ID: 28845861
[TBL] [Abstract][Full Text] [Related]
19. Managing distorted ABSORB Scaffold in left main during anomalous LMCA stenting.
Rath PC; Reddy KC; Agarwala MK; Purohit BV
Indian Heart J; 2015; 67(3):268-70. PubMed ID: 26138187
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a fully bioresorbable vascular scaffold in patients with coronary artery disease: design of and rationale for the ABSORB III randomized trial.
Kereiakes DJ; Ellis SG; Popma JJ; Fitzgerald PJ; Samady H; Jones-McMeans J; Zhang Z; Cheong WF; Su X; Ben-Yehuda O; Stone GW
Am Heart J; 2015 Oct; 170(4):641-651.e3. PubMed ID: 26386787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
